The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, prospective, multicenter, Proof of Concept, Phase II clinical trial
Study. The main objective of the study is to evaluate the efficacy (meant as overall response
rate ORR) of TT (targeted Therapy) vs SoC (standard of Care) in patients with progressive
disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors,
non small cell lung cancer (NSCLC) or others. Patients should have completed at least 1 line
of treatment and no more than 2 as defined by the current version of the AIOM (Italian
Association of Medical Oncology) guidelines. Patients are included if surgery is
contraindicated.